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The aim of the present study was to investigate whether smoking patients with chronic bronchitis (CB) and recurrent 
exacerbations show signs of depressed cell-mediated immunity (CMI), as reflected in the cutaneous delayed-type 
hypersensitivity (DTH) reaction, in comparison with asymptomatic smokers and healthy never-smokers. 
The study was a comparative clinical study performed at a university hospital center of respiratory medicine. 
Sixteen smokers with stable CB and recurrent exacerbations, five of whom had mild airflow obstruction, 18 
asymptomatic smokers and 18 healthy never-smokers, all aged between 35 and 64 years, participated. No subjects 
treated with corticosteroids or N-acetylcysteine were included. Cutaneous DTH-reactions to seven recall antigens 
were assessed with Multitest@, a standardized in viva test of clinical CMI. Reactions were assessed 48 h after 
application by measurement of skin induration. A score (sum in mm of positive reactions) was created to assess 
overall reactivity. 
Neither the score nor the number of positive reactions differed significantly between the three study groups. Men 
had a significantly higher reactivity than women (PcO.05) irrespective of group affiliation. No influence of smoking 
status on DTH reactivity could be seen. In the CB group no correlation was found between DTH reactivity and 
number of exacerbations the past 2 years. Patients with chronic bronchitis and recurrent exacerbations did not differ 
from asymptomatic smokers or healthy never-smokers with respect to cutaneous DTH reactions. Depression of 
CMI, as measured in this study, does not seem to be a primary factor behind recurrent exacerbations in smokers 
with CB. 
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Introduction 
Tobacco smoking induces profound immunological and 
inflammatory changes, both locally in the airways and 
systemically (1). Smoking impairs host defences and 
increases susceptibility to infection (2,3), but the reason 
why only some smokers develop problems with repeated 
respiratory tract infections is largely unknown. The dis- 
position for airway infections seen in some smokers seems 
to be related to the presence of chronic bronchitis (CB) (4). 
The predominant manifestation of infection in patients with 
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CB is the exacerbation where a bacterial or viral cause can 
be demonstrated in the majority of cases (5-7). These 
exacerbations occur recurrently and often result in repeated 
courses of antibiotic treatment and hospital admissions 
(83. 
Impairment of cell-mediated immunity (CMI), induced 
by smoking or by other mechanisms, is one of several 
possible explanations for the increased susceptibility to 
bronchial infections in this patient group. Different aspects 
of CM1 have been investigated previously in patients with 
CB or chronic obstructive pulmonary disease (COPD) 
and recurrent exacerbations. Reports of decreased blood 
monocyte chemotaxis (10) as well as defective monocyte 
candidacidal ability (11) have been presented. In addition, 
decreased phagocytosis (12) and candidacidal ability (13) of 
neutrophil granulocytes have been reported. Depressed 
mitogen- and antigen-stimulated proliferation of blood 
lymphocytes has also been described (14). 
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As an in vivo measure of clinical CMI, the delayed-type 
hypersensitivity (DTH) reaction to different recall antigens 
has been used. The role of smoking for DTH reactivity is 
not known, but several researchers have described 
decreased DTH reactions indicative of defect CM1 in 
patients with CB (12,13,15). In these studies, most patients 
were in an advanced stage of disease with significant 
chronic airflow obstruction. This could be of importance 
since malnutrition with low body weight, a condition 
strongly associated with depressed DTH reactivity (16,17), 
is common in this patient group (18-20). The question 
of whether the depressed DTH reactivity was a primary 
phenomenon connected with recurrent infections and the 
development of chronic airflow obstruction, or only 
secondarily associated with an advanced disease stage, was 
not addressed in these studies. 
The aims of the present study were to investigate whether 
patients with CB and recurrent infectious exacerbations 
without advanced disease show a lower reactivity to a 
standardized DTH test compared to smoking and non- 
smoking controls, and to analyse the possible influence of 
smoking per se on systemic recall immunity as reflected in 
DTH-reactivity. To control for the possible confounding 
influence of malnutrition on DTH reactivity, calculation of 
body mass index (BMI) was done in all participating 
subjects. 
Materials and Methods 
DESIGN 
Delayed cutaneous hypersensitivity to seven recall antigens 
was studied in three well-defined study groups: patients 
with CB and recurrent exacerbations, asymptomatic 
smokers and healthy never-smokers. The study forms part 
of a comprehensive investigation, exploring different 
aspects of airway and systemic immunity in patients 
with CB and recurrent exacerbations and asymptomatic 
smokers, parts of which have been presented previously 
(21). The third study group of healthy never-smokers was 
added after the completion of the study of the two smoking 
groups. Identical methods and criteria for inclusion and 
exclusion of the subjects were used. 
The subjects were recruited from patient files at the 
department of respiratory medicine and by advertising in 
a daily newspaper. A medical examination and a lung 
function test took place at visit one. Height and weight 
for calculation of BMI (BMI= weight x height - “) were 
registered. At a second visit within 2 weeks thereafter, a test 
for cutaneous DTH reactions was performed and was 
evaluated 48 h later. 
The study was approved by the ethics committee at the 
University of Giiteborg. The subjects gave their written 
consent after both written and oral information about the 
study. 
SUBJECTS 
Two control groups, each with 18 subjects, were studied. 
The first was composed of healthy never-smokers (NS) with 
normal lung function defined as forced expiratory volum 
in the first set (FEV,) >80% of predicted (pred.) norma 
value based on gender, age and height. Asymptomatic 
smokers (AS) with normal lung function as defined above 
made up the second control group. They were all curren 
smokers, having smoked for more than 10 years ant 
consuming at least 10 cigarettes per day without fulfilling 
the American Thoracic Society (ATS) criteria of chronic 
bronchitis (22). 
The patient group was composed of 16 subjects with 
symptoms of CB as defined by ATS (22), i.e. chronic or 
recurrent productive cough on most days for a minimum of 
3 months per year during the past 2 years. Co-existing 
chronic airway obstruction defined as FEV, 180% pred. 
was allowed. All were current smokers, having smoked for 
more than 10 years and consuming at least 10 cigarettes per 
day. All had a history of two or more acute exacerbations 
during the past 12 months as defined by Boman et al. (23), 
i.e. mucopurulent or purulent sputum and an increase 
(compared to usual) in one of the following symptoms: 
cough, sputum volume, breathlessness, difficulty of 
expectoration. The total number of exacerbations during 
the past 2 years was recorded. 
Subjects between 35 and 65 years of age were chosen for 
the study. 
Criteria for exclusion were: treatment with 
N-acetylcysteine (NAC), antihistamines or antibiotics, 
vaccination or other immunomodulating treatment within 
4 weeks prior to the first investigation, glucocortico- 
steroid treatment (oestrogen included), whether local or 
systemic, or other immunosuppressant treatment within 3 
months prior to the first investigation, and symptoms of 
infectious respiratory disease within 4 weeks prior to the 
investigation. 
Subjects were also excluded if they had: a baseline FEV, 
~45% pred., a post-bronchodilator increase in FEV, > 15% 
pred., abnormal chest radiograph, other active pulmonary 
diseases such as sarcoidosis, cystic fibrosis, a,-antitrypsin 
deficiency or a history of asthma, known immuno- 
deficiency, significant skin diseases, e.g. contact allergy, 
eczema or atopy and other concurrent severe diseases. 
LUNG FUNCTION TEST 
Ventilatory lung function (FEV,% pred.) was measured 
with a Vitalograph Alpha (Vitalograph Ltd, Buckingham, 
U.K.) in a standardized manner according to the directions 
of the European Coal and Steel Community (24). 
DELAYED-TYPE HYPERSENSITIVITY TEST 
A cutaneous DTH test (Multitest@CMI, Pasteur Merieux, 
Lyon, France) was applied at visit two. The Multitest 
system consists of a plastic disposable multipuncture 
device, by which low concentrations of seven glycerinated 
antigens (tetanus, diphtheria, Streptococcus, tuberculin, 
Candida. Trichophyton and Proteus) and a glycerinated 
negative control are administered simultaneously by prick- 
puncture. The inner surface of one of the forearms was 
used. 
TABLE 1. Demographic and clinical data 
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Never-smokers 
Asymptomatic CB with 
smokers exacerbations 
n 
Age (years) 
BMI (kg m - ‘) 
FEV,% pred. 
Pack years 
Current smoking, cigarettes day - 
Male/female 
Duration of CB (years) 
Exacerbations in 2 years (n) 
18 18 
46 (36-64) 45* (35-58) 
23 (20-38) 24 (20-32) 
1051,$ (93-136) 93 (81-114) 
0 28 (15-57) 
0 20 (10-30) 
8110 7111 
0 0 
0 0 
16 
53 (38-63) 
25 (23-35) 
88 (62-124) 
29 (16-44) 
20 (10-30) 
4112 
8 (4-26) 
7 (4-12) 
Data are presented as median values with range in parenthesis. CB: chronic bronchitis; BMI: body 
mass index. 
*asymptomatic smokers vs. CB group, PcO.05; tnever-smokers vs. asymptomatic smokers, PcO.05; 
$never-smokers vs. CB group, P<O.OOl. 
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FIG. 1. (a) Median and individual scores (sum in mm of positive cutaneous reactions) in DTH test. (b) Individual number 
of positive DTH reactions. The dashed line marks the upper limit of hypoergic responses. 0, Never-smokers; 0, asympto- 
matic smokers; l , chronic bronchitis patients. 
One investigator performed all applications according to 
the instructions of the manufacturer, and the reactions were 
assessed 48 i 4 h later by the same investigator. Reactions 
were assessed by measuring the skin induration in two 
perpendicular diameters. A skin induration with a mean of 
the two diameters of 22 mm was considered to be a 
positive reaction. 
The definitions of hypoergylanergy and the scoring 
system for evaluation of overall reactivity proposed by 
Kniker et al. (25) were used. Accordingly, the total score for 
each individual was defined as the sum in millimeters of all 
positive reactions, and hypoergy as fewer than three posi- 
tive reactions. Anergy was defined as no positive reaction. 
STATISTICAL CONSIDERATIONS 
A StatView@ 4.5 (Abacus Concepts, Berkeley, CA, U.S.A.) 
software package was used for the statistical analysis. As 
most of the data did not show a normal distribution, data 
are presented as median and range unless otherwise stated. 
For comparisons between groups, a Kruskal-Wallis test 
was performed, followed by Wilcoxon rank-sum tests with 
Bonferroni corrections for multiple comparisons when 
appropriate. P-values ~0.05 were accepted as significant. A 
Spearman rank correlation coefficient was calculated to 
investigate correlations between clinical variables. 
Results 
A total of 52 subjects (18 NS, 18 AS and 16 CB patients) 
were enrolled and completed the study. All subjects were 
Caucasian and from the west coast of Sweden. Subject 
demographic and clinical data are presented in Table 1. 
BMI did not differ significanly between the three study 
groups and there were no individuals with a low BMI 
(normal range 19-25) (26). 
The number and size of positive reactions to the seven 
different antigens of Multitest@ CM1 are presented in 
Table 2. The three antigens with the largest number of 
positive reactions were tuberculin, tetanus and diphtheria in 
all three groups. In order to analyse whether reactivity to 
the different individual antigens differed between the 
groups, the number and size of reactions to antigens with a 
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TABLE 2. Number and size of positive reactions to seven antigens in Multitest@ 
Antigen 
Never-smokers 
(n= 18) 
Asymptomatic smokers 
(n= 18) 
CB with exacerbations 
(n= 16) 
Tetanus 14 6.25 (2-12.5) 14 7 (3.5-10.5) 11 7.25 (3.5-13) 
Diphtheria 7 4.5 (2-9.5) 8 4 (2-11) 8 5 (2.5-12,5) 
Streptococcus 1 2.5 1: 2.5 Q-4) 2.5 (2-3,25) 
Tuberculin 9 4.5 (2-8.5) 4 (2-14.5) 
1: 
4.5 (4-9.5) 
Candida 2 3.0 (3) 3 4.5 (2.5-g) 6 3 (2-3.75) 
Trichophyton 3 3.0 (2-3) 3 4 (2.5-4.5) 0 - 
Proteus 5 3.5 (2-5) 5 3 (2-3.5) 8 3 (2<5) 
Sizes in mm; median values are shown with ranges in parenthesis. CB: chronic bronchitis. 
positive reaction in five or more subjects in each group 
(tetanus, diphtheria, tuberculin and Proteus) were com- 
pared between the groups. No significant differences were 
found. 
The individual scores and number of positive reactions in 
each individual are presented in Fig. l(a) and (b). There 
were no significant differences between the groups in DTH 
score or in number of positive reactions. The median 
scores were 11, 12.25 and 15.25 mm, in the NS, AS and 
CB groups, respectively. The median number of positive 
reactions was 3 in all groups. Hypoergy was found in 8/18 
[44%), S/18 (44%) and 6/16 (38%) patients in the NS, AS 
and CB groups, respectively. Two subjects in the AS group 
were anergic. 
Five subjects in the CB group had mild airflow 
obstruction (FEV,% pred. median 71, range 62-79). They 
did not differ significantly from the non-obstructive subjects 
with respect to age, sex, smoking history, duration of CB or 
number of exacerbations. Their median DTH score was 
lower than that of the other 11 CB patients (15 KY. 
17.5 mm), but the difference was not significant. They also 
had a slightly lower median BMI than that of the non- 
obstructive patients (24 vs. 27) but this difference was not 
statistically significant. 
A significant difference (PcO.05) in DTH score was noted 
between the male and female subjects in the total popula- 
tion with a median score of 17.5 mm in men and Il.5 mm in 
women. As men and women were unevenly distributed 
between the study groups, a comparison of each sex separ- 
ately was performed. No significant difference between the 
groups was found for either sex. 
In order to investigate the relationship between DTH 
reactivity and clinical variables in the CB group, a Spear- 
man rank correlation coefficient was calculated between the 
results of the skin test, using both score and number of 
positive antigens and 1. the number of exacerbations during 
the past 2 years and 2. FEV,% pred. No significant 
correlations were found. 
MULTIPLE LINEAR REGRESSION ANALYSIS 
To analyse further the relative influences on the DTH score 
of gender, smoking status, BMI and age, these variables 
were entered into a multiple regression model as indepen- 
dent variables with DTH score as the dependent variable. 
The results are shown in Table 3. The R2-statistic for the 
model was 0.201, i.e. 20% of the total variation in DTH 
score was explained by the model. Gender had a statistically 
significant influence on DTH score whereas no significant 
influence could be demonstrated for either smoking, BMI 
or age. 
Discussion 
In the present study, we investigated one aspect of cell- 
mediated immunity, the cutaneous DTH reaction to recall 
antigens, in a well-defined group of patients with CB and 
recurrent exacerbations compared with asymptomatic 
smokers and healthy never-smokers. We found no sign of 
depressed DTH reactivity in our patient group when com- 
pared with either of the control groups and we could not 
demonstrate any significant influence of smoking, BMI or 
age on DTH reactivity. We found a significantly lower 
reactivity in women than in men. 
The rationale to study DTH responses in CB patients 
with recurrent exacerbations is based on results from pre- 
vious studies (from the fields of oncology and surgery) 
where a reduced DTH response was found to be indicative 
of a clinically significant impair~ment of CM1 (27,28). The 
DTH reaction represents a combination of immunological 
TABLE 3. Multiple linear regression of DTH score on 
gender, smoking status, BMT and age 
Variable Coefficient SEM CI P-value 
Gender 7.25 2.59 (2.05; 12.45) 0.007 
Smoking status 3.73 2.60 (- 1.51; 8.97) 0.16 
BMI 0.41 0.31 (-0.21; 1.04) 0.19 
Age -0.09 0.17 (- 0.42; 0.25) 0.59 
DTH: delayed-type hypersensitivity; BMI: body mass 
index; SEM: standard error of the mean; CI: 95% confidence 
interval. 
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reactions that can be studied in vitro including lymphocyte 
transformation and proliferation in response to specific 
antigen stimulation, lymphokine production and monocyte 
migration. Although it must be emphasized that the DTH 
reaction does not give complete information on the immu- 
nological mechanisms involved in cell-mediated immunity, 
a correlation between low DTH reactivity and reduced 
lymphocyte reactivity in vitro upon stimulation with phyto- 
haemagglutinin (PHA) or tetanus has been found in several 
studies (13,29,30). In addition, an association between low 
DTH reactivity and reduced blood neutrophil and alveolar 
macrophage candidacidal ability has been described (15). 
The Multitest@ CM1 system used in the present study of 
DTH reactivity tests the capacity of the individual to mount 
a cell-mediated immune response to seven recall antigens. It 
is assumed that the antigens are common in the environ- 
ment and that most adults have already been exposed 
to them, either via childhood immunization or natural 
exposure. The reliability and reproducibility of the test has 
been demonstrated previously (25,31,32). Several studies 
have indicated that gender is important in determining 
responsiveness (with smaller responses in women) (33,34), 
an observation which is confirmed by our results. Data on 
the effect of increasing age are somewhat conflicting but 
most studies indicate reduced responses in ages over 70 
years (29,30,33,35). Apart from age and gender, a number 
of other factors may influence DTH reactions, such as 
immunosuppressive therapy, malnutrition (16,17), recent 
infection (3 I), surgical trauma (36) and malignancies (37). 
As to the possible effect of smoking, the response to 
tuberculin was investigated in smokers and non-smokers by 
Onari et al. (38) with no differences found between the 
groups. In the present study, the inclusion and exclusion 
criteria were chosen to minimize undesired influences on the 
test result. In spite of this, multiple regression analysis of 
DTH score showed that only a relatively small fraction of 
the variation could be explained by registered factors. 
Based on previous studies, we hypothesized that DTH 
reactions would be lower in the group with CB and 
recurrent exacerbations but found no support for this 
hypothesis. Instead, the mean size of positive reactions was 
largest in the Cl3 group although this difference was small. 
Our CB group was dominated by women, known to have a 
lower reactivity than men. Hypothetically, an equal 
distribution of men and women in all three study groups 
might have resulted in a higher DTH reactivity in the CB 
group. 
Our results differ from those of several previous studies 
where depressed DTH reactions have been reported in CB 
and COPD patients with a history of recurrent exacer- 
bations (12,13,15). Hypothetically, smoking status could be 
of importance for DTH reactivity. In the referred studies 
smoking history is either not reported or not comparable 
between patient and control groups (12,13,15). The design 
of the present study with two control groups, one with 
similar smoking history and present smoking habits to 
those of the CB group and one with never-smokers, enabled 
us to analyse the influence of smoking per se’ on DTH 
reactivity. Our results, however, indicate that smoking has 
no depressive effect on DTH reactivity, and consequently 
that this cannot explain the differencies between the present 
and the previous studies. 
There are other discrepancies in patient selection which 
might explain the differing results. Firstly, there are differ- 
ences in disease stage. Thirty-one per cent (5/16) of our CB 
patients had airflow obstruction. In one of the earlier 
reports (12), the fraction of patients with airflow obstruc- 
tion was similar (31%), whereas in the other two reports 
(13,15), all (100%) patients had airflow obstruction. 
Furthermore, where reported (13), the degree of airflow 
obstruction was higher than in our CB patients. This would 
seem to indicate an association between impaired DTH 
reactivity and a more advanced state of inflammatory 
airways disease with airflow obstruction, an association not 
discernible in our patients with no or mild airflow obstruc- 
tion. There is, however, another factor associated with 
severe airflow obstruction that might influence DTH 
reactivity. Body weight was strongly related to FEV, in a 
large study of COPD patients by Wilson et al. (19) and 
malnutrition is a common condition in these patients 
(16,20). Furthermore, depressed DTH reactivity is a com- 
mon feature of malnutrition (16,17). Although we have no 
knowledge of the nutritional status of the subjects in the 
referred studies, it is reasonable to speculate that the 
depressed DTH reactivity found in these patients with a 
more advanced disease stage could coincide with a state of 
malnutrition. In our patients with no or mild airflow 
obstruction and with normal or high BMI in all cases, there 
is no such connection. 
Secondly, age might be of importance. All participants in 
our study were between 35 and 65 years, a range where 
DTH reactivity can be expected to be relatively constant. 
The minimal influence of age on DTH score in our subjects 
would seem to support this supposition. In the referred 
studies however, mean ages were close to or above the 
upper limit of this interval, where relatively small differ- 
ences in mean age between patient and controls groups 
might be of importance. Whatever the cause might be for 
the previous findings of depressed DTH reactivity in CB 
and COPD patients, it can be of clinical relevance. How- 
ever, it seems to be related to advanced disease stages, and 
not primarily to smoking. 
To conclude, we found no sign of impaired cell-mediated 
immunity by one measurement in smoking patients with 
chronic bronchitis and recurrent exacerbations. This result 
gives no support to the hypothesis that depressed cell- 
mediated immunity is a primary factor behind recurrent 
exacerbations or the progression to chronic air-how 
obstruction in this patient group. 
Acknowledgements 
The authors would like to thank study nurse Ann-Marie 
Hilmersson and study monitor Ann-Btitt Liifroos for their 
excellent work in connection with this study. 
This study received financial support from: Clinical 
Research and Development, Astra Dtaco AB, Lund, 
Sweden; The Swedish Heart-Lung Foundation; The Society 
of Medicine in Goteborg, Sweden. 
496 ~.QVARFORDT ETA 
References 16. 
1. 
2. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
Holt PG. Immune and inflammatory function in 
cigarette smokers. Thorax 1987; 42: 241-249. 
Aronson MD, Weiss ST, Ben RL, Komaroff AL. 
Association between cigarette smoking and acute 
respiratory tract illness in young adults. JAMA 1952; 
248: 181-183. 
Marcy TW, Merril WW. Cigarette smoking and respir- 
atory tract infection. Clin Chest Med 1987; 8: 381-391. 
Fletcher C: Peto R. The natural history of chronic 
airflow obstruction. Br Med J 1977; 1: 1645-1648. 
Busch0 RO, Saxtan D, Shultz PS, Finch E, Mufson 
MA. Infections with viruses and Mycoplasma pneumo- 
niae during exacerbations of chronic bronchitis. J Infect 
Dis 1978;137:377-383. 
Fagon J-Y, Chastre J, Trouillet J-L et al. Characteri- 
zation of distal bronchial microflora during acute 
exacerbation of chronic bronchitis. Am Rev Respir Dis 
1990; 142: 1004-1008. 
Monso E, Ruiz J, Rose11 A et al. Bacterial infection in 
chronic obstructive pulmorary disease: a study of stable 
and exacerbated outpatients using the protected 
specimen brush. Am J Respir Crit Care tied 1995; 152: 
1316-1320. 
Anthonisen NR, Manfreda J, Warren CPW, Hershfield 
ES, Harding GKM, Nelson NA. Antibiotic therapy 
in exacerbations of chronic obstructive pulmonary 
disease. Arm Intern Med 1987; 106: 196-204. 
Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. 
Acute infective exacerbations of chronic bronchitis. Q J 
Med 1995;88: 61-68. 
Nielsen H, Bonde J. Association of defective monocyte 
chemotaxis with recurrent acute exacerbations in 
chronic obstructive lung disease. EUJ, J Respir Dis 1986; 
68: 200-206. 
Vecchiarelli A, Dottorini M, Puliti M, Todisco T, 
Cenci E, Bistoni F. Defective candidacidal activity of 
alveolar macrophages and peripheral blood monocytes 
from patients with chronic obstructive pulmonary 
disease. Am Rev Respir Dis 1991; 143: 1049-1054. 
Fietta A, Bersani C, De Rose V et al. Evaluation 
of systemic host defence mechanisms in chronic 
bronchitis. Respiration 1988; 53: 3743. 
Todisco T, Vecchiarelli A, Dottorini M et al. 
Interferon-gamma (r-IFN-y) induced activation of 
alveolar macrophages (AM) from anergic patients with 
chronic obstructive pulmonary disease. J Biol Reg 
Homeostat Agents 1992; 6: 87-92. 
Schiinfeld N; Remy N, Bartmann P, Wahn U, 
Loddenkemper R. In vitro Untersuchungen zur cel- 
lularen Immunitat bei chronischen Bronchitikern mit 
und ohne Kortikosteroidmedikation. Pneumologie 
1992; 46: 179-182. 
Baglioni ST Dottorini M: Sini GM, Eslami A, 
Vecciarelli A, Todisco T. Prediction of pulmonary 
immunodeficiency in chronic bronchitis by cutaneous 
hypoergy to multitest. Dev Biol Stand 1992; 77: 
167-173. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
2.5. 
26. 
27 
28 
29 
Wilson DO, Rogers RM, Hoffman RM Nutrition ant 
chronic lung disease. Am Rev Respir Dis 1985; 132 
1347-1365. 
Cason J, Ainley CC, Wolstencroft RA, Norton KR 
Thompson RP. Cell-mediated immunity in anorexi: 
nervosa. Clin Exp Inzmu~zol 1986; 64: 370-375. 
Driver AC, McAlevy MT, Smith JL. Nutritiona. 
assessment of patients with chronic obstructive 
pulmonary disease and acute respiratory failure. Chesl 
1982; 82: 568-571. 
Wilson DO, Rogers RM, Wright EC, Anthonisen NR. 
Body weight in chronic obstructive pulmonary disease. 
Am Rev Respir Dis 1989; 139: 1435-1438. 
Engelen MPKJ, Schols AMWJ, Baken WC, Wesseling 
GJ, Wouters EFM. Nutritional depletion in relation to 
respiratory and peripheral skeletal muscle function 
in out-patients with COPD. Eur Respir J 1994; 7: 
1793-1797. 
Qvarfordt 1, Riise GC, Larsson S et al. Immunological 
findings in blood and bronchoalveolar lavage fluid in 
chronic bronchitis patients with recurrent infectious 
exacerbations. Eur Respir J 1998; 11: 46-54. 
Official Statement of the American Thoracic Society. 
Standards for the diagnosis and care of patients with 
chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med 1995; 152 (Suppl. 5): Sl7-S120, S78. 
Boman G, Backer U, Larsson S, Melander B, 
Wahlander L. Oral acetylcysteine reduces exacerbation 
rate in chronic bronchitis: report of a trial organized by 
the Swedish Society for Pulmonary Diseases. Eur J 
Respir Dis 1983; 64: 405-415. 
Quanjer PH. Standardized lung function testing. 
Report of a Working Party on Standardization of Lung 
Function Tests. European Community for Coal and 
Steel. Bull Europ Physiopath Respir 1983; 19 (Suppl. 5): 
l-95. 
Kniker WT, Anderson CT, McBryde JL, Roumiantzeff 
M, Lesourd B. Multitest CM1 for standardized 
measurement of delayed cutaneous hypersensitivity and 
cell-mediated immunity. Normal values and proposed 
scoring system for healthy adults in the U.S.A. Ann 
Allergy 1984; 52: 75-82. 
Ferro-Luzzi A, Sette S, Franklin M, James WPT. A 
simplified approach of assessing adult chronic energy 
deflency. Eur J Clin Nutr 1992; 46: 173-186. 
Sokal JE. Editorial: measurement of delayed skin-test 
responses, N Engl J Med 197.5; 293: 501-502. 
MacLean LD. Delayed type hypersensitivity testing 
in surgical patients. Surg Gynecol Obstet 1988; 166: 
285-293. 
Girard JP, Paychere M, Cuevas M, Fernandes B. 
Cell-mediated immunity in an aging population. Clin 
Exp Immunol 1977; 27: 85-91. 
30. Gordon EH, Krouse HA, Kinney JL, Stiehm ER, 
Klaustermayer WB. Delayed cutaneous hypersensitiv- 
ity in normals: choice of antigens and comparison to in 
vitro assays of cell-mediated immunity. J Allergy Clin 
Immunol 1983; 72: 487494. 
31. Lesourd BM, Wang A, Moulias R. Serial delayed 
cutaneous hypersensitivity skin testing with multiple 
CUTANEOUS DELAYED-TYPE HYPERSENSITIVITY IN CHRONIC BRONCHITIS 497 
recall antigens in healthy volunteers: booster effect 
study. Ann Allergy 1985; 55: 729-735. 
32. Frazer IH, Collins EJ, Fox JS, Jones B, Oliphant RC, 
Mackay IR. Assessment of delayed-type hyper- 
sensitivity in man: a comparison of the ‘Multitest’ and 
conventional intradermal injection of six antigens. Clin 
Immunol Immunopathol 1985; 35: 182-190. 
33. Maxwell AP, McCluskey DR. Assessment of cell- 
mediated immunity in a British population using 
multiple skin test antigens. Clin Allergy 1986; 16: 
365-369. 
34. Moesgaard F, Lykkegaard-Nielsen M, Norgaard- 
Larsen P, Christophersen S, Mosbech H. Cell-mediated 
immunity assessed by skin testing (Multitest@). Allergy 
1987; 42: 591-596. 
35. Marrie TJ, Johnson S, Durant H. Cell-mediated 
immunity of healthy adult Nova Scotians in various 
age groups compared with nursing home and hospital- 
ized senior citizens. J Allergy Clin Immunol 1988; 81 (5 
Pt 1): 836843. 
36. Berti Riboli E, Terrizzi A, Arnulfo G, Bertoglio S. 
Immunosuppressive effect of surgery evaluated by the 
multitest cell-mediated immunity system. Can J Surg 
1984; 27: 60-63. 
37. Czarnecki D, Zalcberg J, Kulinskaya E, Kay T. 
Impaired cell-mediated immunity of apparently normal 
patients who had multiple skin cancers. Cancer 1995; 
76: 228-23 1. 
38. Onari K, Sadamoto K, Takaishi M et al. Immunologi- 
cal studies on cigarette smokers. Part II. Cell mediated 
immunity in cigarette smokers and the influence of the 
water-soluble fraction of cigarette smoke (WSF) on the 
immunity of mice. Hiroshima J Med Sci 1980; 29: 
29-34. 
